Opioid Induced Constipation Drugs Market Analysis

Opioid Induced Constipation Drugs Market Analysis

To get key market trends

  Download Free Sample

The opioid induced constipation drugs industry by drug class is categorized into peripherally acting mu-opioid receptor agonists (PAMORAs), chloride channel-2 activators, laxatives, proton pump inhibitors, anti-diarrheal, and other drug classes. The peripherally acting mu-opioid receptor agonists (PAMORAs) segment was reached USD 706.3 million in 2023.
 

• PAMORAs represent a class of pharmaceuticals specifically designed to alleviate constipation associated with opioid use, addressing a critical need in patient care. PAMORAs distinguish themselves by selectively targeting peripheral mu-opioid receptors in the gastrointestinal tract, offering a mechanism of action tailored to the specific challenges of opioid-induced constipation. This distinct approach ensures the efficacy of PAMORAs in alleviating constipation while preserving the analgesic effects of opioids.  
   
• Moreover, the ability of PAMORAs to enhance bowel function goes beyond mere symptomatic relief, fostering improved patient satisfaction. By promoting regular bowel movements, patients experience a tangible improvement in their overall well-being. Due to such advantages, the segment is anticipated to grow over the forecast period.
   

The opioid induced constipation drugs market by prescription type is categorized into prescribed drugs and over-the-counter (OTC) drugs. The prescribed drugs segment exceeded USD 1.3 billion in 2023.
 

• The dominance of prescribed drugs in OIC treatment underscores the reliance on specialized pharmacotherapy to effectively manage constipation induced by opioid medications. Healthcare providers often opt for prescription-based solutions that specifically target the gastrointestinal complications associated with opioids, offering patients tailored and clinically proven options to alleviate OIC symptoms.  
   
• Notable prescribed drugs like naloxegol, lubiprostone, and naldemedine form the cornerstone of OIC treatment. These medications have demonstrated significant efficacy in addressing opioid-induced constipation and are widely recognized for their therapeutic benefits. The inclusion of such major prescribed drugs further solidifies the dominance of pharmaceutical interventions in OIC management, showcasing their effectiveness in alleviating constipation symptoms associated with opioid use, driving segmental growth.
   

Based on the route of administration, the opioid induced constipation drugs market is segmented into oral and injectable. The oral segment is anticipated to reach USD 2.4 billion by 2032.
 

• Oral medications provide a convenient and non-invasive way for individuals to manage constipation associated with opioid use. These oral drugs contribute to the growth of OIC treatment by enhancing patient compliance. The ease of oral administration aligns with patient preferences, fostering higher adherence to prescribed regimens. This improved compliance results in more effective constipation management, positively impacting patient outcomes and reinforcing the role of oral drugs in the overall treatment paradigm.
   
• Further, the availability of diverse oral therapeutic options for OIC further propels their role as a growth driver. Patients have access to a range of oral medications specifically designed to address opioid-induced constipation, allowing healthcare providers to tailor treatment plans based on individual patient needs. This diversity in oral drug offerings amplifies their significance in the comprehensive management of OIC, contributing to the market growth positively.
   

The opioid induced constipation drugs market by distribution channel is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominates the market with a revenue around USD 1 billion in 2023.
 

• Hospital pharmacies serve as central points where patients receive medical care and obtain their prescribed medications. They have direct access to patients who may require treatment for opioid induced constipation. This increased access to patients makes the hospital pharmacies the prominent distributer of the opioid induced constipation.
   
• Moreover, hospitals pharmacies have facilities equipped to store opioid induced constipation under appropriate conditions to maintain their stability and integrity. They adhere to strict guidelines and regulations for the storage and handling of medications to ensure their safety and efficacy.
   

North America opioid induced constipation drugs market size surpassed USD 858.2 million in 2023 and is predicted to witness substantial market growth over 2024-2032.
 

• The advanced healthcare infrastructure in North America plays a pivotal role in fostering the growth of opioid induced constipation drugs. With well-established healthcare systems and a focus on comprehensive patient care, the region is at the forefront of addressing opioid-related complications. This includes the need for effective medications to manage constipation, contributing to the robust demand for OIC drugs and driving market expansion.
   
• Moreover, North America experiences a notable increase in the prevalence of gastrointestinal disorders, compounding the challenges associated with opioid-induced constipation. For instance, according to an article published by Medscape, in 2020, in North America alone, chronic constipation affected approximately 63 million people. The co-occurrence of opioid use and gastrointestinal disorders intensifies the demand for specialized OIC drugs, reflecting the interconnected nature of these healthcare concerns, further fueling demand.